Q3 2020 Sales Performance

Pharmaceuticals Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. £17.6bn, flat CER Sales turnover 2019 Key Products Tivicay/Triumeq/2DRS* HIV Trelegy Nucala Zejula Benlysta COPD Severe Asthma Oncology Immuno-inflammation * 2DR = 2 drug dolutegravir-based regimens such as Dovato and Juluca Immune system T-cells attacking a cancer cell

View entire presentation